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The early years The immunology section of the Liver Unit began, like so many other research areas in those early days, as a foray into the unknown by enthusiastic but relatively inexperienced research fellows. During an eventful year as a medical registrar at Dulwich Hospital in 1967, Adrian Eddleston was enlisted as both injector of Technetium sulphur colloid in the Physics Department at King's and interpreter of the resulting liver scintiscans, and soon found that his appetite for research first kindled in Oxford, was alive and well. Hot spleens and cold livers, the norm in cirrhosis, were tracked down to changes in blood flow in the two organs, after some stimulating discussions with Laurie Blendis, an uncompromising but wonderfully stimulating research mentor. ' Adrian joined the research staff of the Liver Unit in the next year, and expressed an interest in studying the immunology of autoimmune liver diseases, an area of almost complete ignorance both generally and at a personal level! The power of effector lymphocytes as opposed to the more popular antibodies was just beginning to be perceived, and as the first step in a steep learning curve, Adrian went to Copenhagen to learn the new technique of leucocyte migration inhibition from its inventors, S0borg and Bendixen, who were interested in the cellular immune basis of organ specific autoimmunity. 2 Autoimmune chronic active hepatitis seemed a promising candidate for an organ specific autoimmune liver disease, and with a crude liver homogenate as an antigenic stimulus in the leucocyte migration inhibition test, Adrian Eddleston began to probe for liver directed cellular autoimmunity. The King's/Cambridge liver transplant programme was just beginning at that time, and there was curiosity as to what the leucocyte migration inhibition test would do in transplant rejection. The results in the first case followed serially, with migration indices measured every other day, were interesting enough to appear in a letter to Nature3! Rejection began on the seventh day, as judged by the upturn in the serum aspartate aminotransferase. Up to that point all migration indices had been normal. On the morning of the eighth day, inspection of the migrations showed that ... the incubator thermostat had stuck and roasted all the samples set up the day before! Sample taken on the ninth and 13th days, however, showed profound leucocyte migration inhibition in the presence of liver homogenate, which promptly disappeared in subsequent samples taken after a burst of increased imnmosuppression. This Control of humoral and cellular immunity and the mystery of tolerance were clearly of considerable potential importance in autoimmunity, and major studies pointing to fundamental defects in immunoregulation were completed by Kayhan Nouri-Aria, Sandro Vento, and Charlie O'Brien. Perhaps Kayan's most original contribution was to describe a steroid correctable defect in nonantigen-specific suppression in autoimmune chronic active hepatitis (Fig 1) which was not present in virus induced, hepatitis B positive cases. 16 Vento and O'Brien concentrated on antigen specific T-cell mediated suppression,"7 a fiercely controversial area of research, and one suspects that their original, and fascinating observations identifying a familial defect in antigen-specific suppressor inducer T-cells (Fig  2) ,181 ' have yet to be fully appreciated.
IMMUNOPATHOGENESIS OF HEPATITIS B VIRUS INFECTION
In the early 70s, the discovery of the 'Australia antigen' now known to be the hepatitis B surface antigen, was a powerful stimulus to the immunology section of the unit. (Fig 3) . 25 We now know that this was the first detection of a conformational determinant in the pre-S antigen/antibody system expressed on hepatitis B virons, and Alberti has most successfully continued to probe this area of interest after his return to Padua. 26 The difficulty in studying cell mediated immunopathogenesis of hepatitis B virus infection in man was that there was no infected cell line which could be used as target cells for studying the cytotoxicity of patients' T cells in vitro. Yet again a new Italian research fellow provided the breakthrough needed. Giorgina Mieli-Vergani, who had come to the unit with her husband Diego Vergani in 1976, suggested preparing hepatocytes by collagenase digestion from a small fragment of the patient's diagnostic or follow up liver biopsy, and using these as targets for the patient's own T cells in a microcytotoxicity assay. Undaunted by most people's scepticism, she proceeded to show the feasibility of this technique in autoimmune chronic active hepatitis,27 and using this autologous, thus histocompatability locus matched system, went on to show that T lymphocytes from patients with chronic hepatitis B virus infection were indeed cytotoxic to hepatocytes from the same individual. 28 The specificity ofthis T cell attack was explored by Mario Mondelli, who showed that polyclonal, and monoclonal antibodies reacting with hepatitis B virus core antigen were able to block the T cell cytotoxicity, while anti-HBe and anti-HBs antibodies did not (Fig 4) .29 Confirmatory evidence that nucleocapsid components were likely to be an important target antigen for cytolytic T cells came from Nicola Naumov who was able to show by direct observation of microcytotoxicity chambers that hepatocytes expressing core antigens were preferentially destroyed by T cells, while those only expressing hepatitis B surface antigen tended to be spared. 30 The advent of successful a-interferon treatment of hepatitis B focused attention on the power of the cytokines, and this has become an increasingly important research area in the Unit in recent years. Graeme Alexander who has played such an important part in directing this work refers in detail to this current research programme in the next article.
IMMUNOPATHOGENESIS OF DRUG INDUCED HEPATITIS
The notion that idiosyncratic drug induced liver injury might be the result of similar mechanisms to that postulated for virus induced disease followed easily from the Unit's earlier work, and became testable when Adrian Eddleston *''""""0'''"'''""''"1""""""""""" """""'"""""""""'''"" ACUTE0HEPAT I T I S H3SAG POS I T I VẼ~~~~~~~~~. The most important discoveries in the organisation of the HLA loci during this period were the discovery of the class II genes, at first DR and then DQ and DP, and the mapping of the complement genes coding for the complement components C4A and C4B between the B and DR loci. Autoimmune chronic active hepatitis is, in many respects, a classical organ specific autoimmune disease, with a female preponderance, circulating autoantibodies, both non-organspecific (antinuclear and antismooth muscle) and organ specific (reacting with the asialoglycoprotein receptor), a clinical association with other organ specific autoimmune diseases, and marked steroid responsiveness. Mackay and Morris provided further evidence in support of this classification when they showed that the disease was strongly associated with HLA Al and B8,3' the antigens found in many of the other organ-specific autoimmune diseases. In 1974, Bob Galbraith, a newly arrived clinical research fellow, confirmed these findings in a series of 57 patients with chronic active hepatitis and suggested, for the first time, that the HLA B8 association was confined to the 'autoimmune' form of the disease, with hepatitis B surface antigen positive cases having a different immunogenetic background.33 The hypothesis that B8 might be associated with a non-antigen specific increase in immune responsiveness, proposed by Eddleston and Williams,9 was supported by a further study from Galbraith, who showed that titres of autoantibodies and antiviral antibodies were higher in B8 positive patients and first degree relatives. 34 group.bmj.com on January 27, 2018 -Published by http://gut.bmj.com/ Downloaded from withdrawal had shown a very high relapse rate, even in those patients who were apparently in complete remission. 43 Hegarty pointed out that there was no evidence as to whether azathioprine, frequently used in combination with prednisolone in autoimmune chronic active hepatitis," was contributing significantly to the control of disease activity. Working from the hypothesis that the effect of azarthioprine might be most apparent in those patients already controlled on combination treatment, Hegarty together with Tony Stellon showed that azathioprine withdrawal in autoimmune chronic active hepatitis was followed by a significantly increased rate ofrelapse over the next few months. 45 Stellon then went on to show that patients successfully established on a combination of azathioprine and prednisolone could be sustained on 2 mg/kg of azathioprine alone,' although the stability of this control was not always as secure as on the combination. These studies have provided a sound factual base for the design of individual therapeutic regimes for patients with autoimmune chronic active hepatitis, in which the power and potential toxicity of steroids, can be married to the relatively safer, slower acting, but less powerful effects of azathioprine.
Ideally, the immunological basis of the effects of these drugs should be well known so that a logical approach to therapy could be adopted. Unfortunately, although some modes of action have been described,'6 and others postulated,47 this still represents a black hole which remains to be illuminated.
